Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 7/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 6/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27334225 | 0.83 | AAK1 (0.46) | SMARCA2SMARCA4 | |
| SCHEMBL30770699 | 0.83 | AAK1 (0.46) | SMARCA2SMARCA4 | |
| SCHEMBL26639099 | 0.80 | CYP3A4 (0.44) | MAPK1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL26791515 | 0.79 | SMN1; SMN2 (0.46) | MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13331893 | 0.78 | AKR1C3 (0.44) | SMARCA2SMARCA4GRM5ARRECQL | |
| SCHEMBL12614704 | 0.78 | HTT (0.37) | HTTMAPK1MEN1LMNAKMT2A | |
| SCHEMBL334383 | 0.75 | ROCK2 (0.46) | SMN1; SMN2SSTR4 | |
| SCHEMBL14903833 | 0.75 | CYP1A2 (0.45) | SMARCA2SMARCA4GRM5ARRECQL | |
| SCHEMBL30872138 | 0.74 | SMARCA2 (0.38) | SMARCA2SMARCA4GRM5ARRECQL | |
| SCHEMBL29272435 | 0.74 | CNR2 (0.44) | SMARCA2SMARCA4GRM5ARRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024003773-A1 | 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS | PFIZER INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230365551-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220223-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220225-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | METAP1, SARS1, RTF1 | SMARCA2 4193/4885SMARCA4 3364/4885GRM5 3499/4885 |
| US-20230365551-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | NHERF1, ACE, METAP1 | SMARCA2 4205/4885SMARCA4 3091/4885GRM5 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.